Tozuleristide

PreclinicalPeptide

BBlaze Bioscience Inc.

Tozuleristide is one of 5 small molecule programs targeting Squamous Cell Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Cell CancerTerminated

Squamous Cell CancerPreclinical

Terminated

Competition

Competitive Landscape

5 competitors in Squamous Cell Cancer

#DrugCompanyPhaseTrials

Erbitux

IImclone

Phase 2

3 2

Bavencio

EMD Serono

Phase 2

1 3

Pucotenlimab

SSun Yat-sen University

Phase 2

1 4

MRG003

SShanghai Miracogen Inc.

Phase 2

1 5

Tozuleristide

BBlaze Bioscience Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

CNS Tumors1 trial

Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery

Completed·BBlaze Bioscience Inc.·Phase 2/3·NCT03579602·118 enrolled

ESS1 trial

Expanded Access for BLZ-100 (Tozuleristide)

No longer available·BBlaze Bioscience Inc.··NCT04343274

Oral Cavity Squamous Cell Carcinoma1 trial

Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma and High-Grade Dysplasia With Tozuleristide, a Fluorescent Tumor Marking Agent

Terminated·UUniversity of Washington·Preclinical·NCT05316688·8 enrolled

Central Nervous System Tumor1 trial

A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System

Completed·JJohn Yu·Phase 2·NCT04743310·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tozuleristide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tozuleristide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tozuleristide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Blaze Bioscience Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Preclinical[1]
Company: BBlaze Bioscience Inc.

Tozuleristide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

CNS Tumors1 trial

ESS1 trial

Oral Cavity Squamous Cell Carcinoma1 trial

Central Nervous System Tumor1 trial

References

Drug Info

Quick Facts

Related News